Researchers in hypertension genetics feel like they are left behind again. It always seems that the 'other' complex diseases are ahead in the race. Evolving new technologies in the form of genome-wide arrays and 'omics' technologies mean that investigators can now potentially identify many novel disease factors in one large-scale experiment. Hypertension research now faces the challenge of where to go next after the first genome-wide association experiments failed to provide robust candidates. In this review, we contemplate the old dilemma of whether such genes may ever be found; however, we believe advancing technologies and plummeting costs of large-scale experiments will contribute to the identification of novel molecules that underlie essential hypertension.